Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Medicine and Dentistry
Adenocarcinoma
20%
Anemia
20%
Antiangiogenic Therapy
9%
Aromatase Inhibitor
20%
B Lymphocyte Receptor
18%
Cancer
100%
Cardiac Catheterization
6%
Central Nervous System
9%
Clinical Trial
6%
Corticosteroid
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
9%
Cytotoxic Chemotherapy
20%
Diffuse Large B-Cell Lymphoma
100%
Echocardiography
100%
Etiology
13%
Genetics
9%
Heart Disease
6%
Hematopoietic Stem Cell Transplantation
13%
Hemolysis
100%
Hemolytic Anemia
100%
Immune Checkpoint Inhibitor
9%
Immunoglobulin Antibody
20%
Immunohistochemistry
9%
Kidney Function
13%
Malignant Neoplasm
20%
Metastatic Breast Cancer
20%
Multiple Myeloma
100%
Myeloma
6%
Platelet
20%
Programmed Death-Ligand 1
9%
Pulmonary Hypertension
100%
Retrospective Study
6%
Thrombocytopenia
20%
Thrombotic Thrombocytopenic Purpura
20%
Pharmacology, Toxicology and Pharmaceutical Science
Atherosclerosis
11%
Boronic Acid Derivative
22%
Bortezomib
22%
Carcinogenesis
11%
Carfilzomib
11%
Cytoprotective Agent
11%
Disease Exacerbation
11%
Drug Resistance
11%
Dyslipidemia
11%
Hypertension
11%
Insulin Resistance
11%
Ixazomib
11%
Lipid Hydroperoxide
11%
Lipoprotein
11%
Low Density Lipoprotein
100%
Low Density Lipoprotein Cholesterol
11%
Metabolic Syndrome X
33%
Methotrexate
33%
Multiple Myeloma
100%
Myeloperoxidase
11%
Overall Survival
33%
Oxidized Low Density Lipoprotein
100%
Primary Central Nervous System Lymphoma
66%
Procarbazine
33%
Progression Free Survival
33%
Proteasome
11%
Proteasome Inhibitor
100%
Rituximab
33%
Temozolomide
100%
Vincristine
33%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
B-Cell Receptor
18%
Genetics
9%
Immune Checkpoint Inhibitor
9%
Loading Drug Dose
16%
Naloxone
100%
Optimal Drug Dose
16%
PD-L1
9%